
- Driving Co-Development of Therapeutic Drugs and Companion …- Development of companion diagnostics (CDx) as powerful tools in precision medicine typically follows one of three pathways: co-development, bridging, and follow-on. Co-development is … 
- Are Liquid Biopsies the Future of Cancer Biomarkers in Diagnosis …- The Current Status for HER2 Testing There is a large portfolio of available human epidermal growth factor receptor 2 (HER2)-targeted therapies that have an associated companion … 
- China Focusing Innovation Through ICH Global Regulatory Vision- Jul 1, 2022 · As these national guidelines and regulations continue to create favorable conditions for development of drug-CDx reagents in China, industry has responded with calls for China’s … 
- Conversations in ASEAN: - DIA Global Forum- Integral to PM are companion diagnostics (CDx), devices designed and developed to select the right patient candidates for the precision drug. Inevitably, this codependent relationship … 
- ICH E17 Guideline on Multi-Regional Clinical Trials- ulti-Regional Clinical Trials (MRCT) is not a new term and has been in use for many decades. It refers to a clinical trial conducted in more than one region under a single protocol and allows … 
- Integral to PM are companion diagnostics (CDx), devices designed and developed to select the right patient candidates for the precision drug. Inevitably, this codependent relationship … 
- December 2020 - DIA Global Forum- Co-development is the most ideal and cost-effective CDx pathway: It is conducive to screening target patients specifically and identifying drug targets accurately, reducing development cost … 
- Molecular Diagnostics with Clinical Utility: Their Promise in …- However, developing tests with rigorously validated clinical utility can be challenging from an evidence generation perspective, as well as in attaining consensus among patients, … 
- Hand-In-Hand with Companion Diagnostics: The Past, The Present, …- Companion diagnostics are a class of diagnostic devices that has become important not only in personalizing therapy for patients, but also for developers of therapeutic products, who must …